Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $239 million versus the consensus estimate of $156.23 million.

GUIDANCE:

Novavax sees Q3 2025 revenue of $495-545 million, versus the consensus of $89.61 million.

Novavax sees FY2025 revenue of $1-1.05 billion, versus the consensus of $1.02 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.